Press Releases

  |  

Escient Pharmaceuticals Appoints Veena Viswanath, Ph.D., as VP of Translational Biology and Drug Discovery

SAN DIEGO, CA; September 23, 2020 — Escient Pharmaceuticals, Inc., an industry-leading, clinical-stage company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, underserved medical needs across a broad range of therapeutic indications, today announced the hiring of Veena Viswanath as Vice President of Translational Biology and Drug Discovery. Prior to this new role, […]

Read More
  |  

Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus

— Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases — Financing round led by Sanofi Ventures and Cowen Healthcare Investments and included new investors Redmile Group and Perceptive Advisors — Jason Hafler, Ph.D., of Sanofi Ventures and Kevin Raidy of Cowen Healthcare Investments join […]

Read More
  |  

Escient Pharmaceuticals Announces Appointment of K. Peter Hirth to Board of Directors

—Co-founder, former CEO of Plexxikon brings proven track record building platform-based companies and delivering novel medicines for patients— SAN DIEGO, CA; September 24, 2019—Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, today announced the appointment of K. Peter Hirth […]

Read More
  |  

Escient Pharmaceuticals Appoints Kristin Taylor, PhD as Vice President and Head of Clinical Development

— Seasoned industry leader to steer Escient’s clinical development and regulatory strategies as it advances first-in-class Mrgpr-focused pipeline — SAN DIEGO, CA; July 17, 2019—Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, announced today that Kristin Taylor, PhD has […]

Read More
  |  

William Hodder Joins Escient Pharmaceuticals as Chief Business Officer

–Industry veteran brings broad leadership expertise to guide growth strategy and business development for San Diego-based GPCR-focused biotech– SAN DIEGO, CA; March 12, 2019—Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, announced today that William Hodder has joined […]

Read More
  |  

Kathleen Sereda Glaub Appointed Independent Director of Escient Pharmaceuticals

–Industry veteran brings extensive corporate development, financing and
company-building expertise as Escient advances first-in-class GPCR-targeted drugs–

SAN DIEGO, CA; October 10, 2018 — Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, announced today that Kathleen Sereda Glaub has been appointed to its board as an independent director.

Read More
  |   Business Wire

Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs

SAN DIEGO–(BUSINESS WIRE)–Escient Pharmaceuticals launched today with the completion of a $40 million Series A financing to advance first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs), Escient will initially pursue therapies for neuro-immuno-inflammatory and autoreactive diseases. The company will use proceeds from the Series A financing, syndicated by The Column Group and 5AM Ventures and joined by Osage University Partners, to build out its team, advance its pipeline, and progress its initial preclinical programs to clinical study.

Read More